Ucb S A (UCBJF) 76.1100 $UCBJF
UCB to Sell Indian Established Brands Portfolio to Dr. Reddy's - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 1:40PM CDT
UCB S.A. (UCBJF) will sell its established brands portfolio in India, to Dr. Reddy's Laboratories Ltd. to focus on core business.
CYTK: 7.26 (+0.19), LCI: 71.15 (+1.92), RDY: 60.41 (+0.22)
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
BIIB: 425.65 (-0.98), ACT: 294.79 (+2.52), VRX: 207.50 (+1.78), PCYC: 258.35 (+0.57), OSIR: 17.56 (+0.84), ACOR: 34.46 (+0.61), HSP: 87.75 (+0.10), AGN: 240.22 (+2.88), MDVN: 132.44 (+0.38), ESRX: 88.85 (+0.38), SHPG: 248.77 (-5.55), ABBV: 62.00 (+1.68), SNY: 52.35 (+0.48), ARNA: 4.55 (+0.01), REGN: 461.39 (+6.35), ABT: 47.15 (+0.15), ENDP: 94.46 (+0.78), AKRX: 52.74 (+1.31), PFE: 35.44 (+0.41), INCY: 93.81 (+1.53), SLXP: 172.96 (+0.15), AMGN: 163.38 (+1.89), MYL: 70.24 (+0.14), LLY: 73.92 (+1.56), BMY: 64.64 (+1.18), GSK: 48.23 (+0.51), ALKS: 63.52 (+0.96), MNKD: 5.25 (unch), OREX: 8.10 (+0.10), NVO: 55.94 (+1.34), ISIS: 65.70 (+1.64), GERN: 4.08 (+0.12), AZN: 69.91 (-0.25), MRK: 57.25 (-0.18), PBYI: 230.48 (+4.03), NVS: 103.58 (+1.01)
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
BIIB: 425.65 (-0.98), ACT: 294.79 (+2.52), VRX: 207.50 (+1.78), PCYC: 258.35 (+0.57), OSIR: 17.56 (+0.84), ACOR: 34.46 (+0.61), HSP: 87.75 (+0.10), AGN: 240.22 (+2.88), MDVN: 132.44 (+0.38), ESRX: 88.85 (+0.38), SHPG: 248.77 (-5.55), ABBV: 62.00 (+1.68), SNY: 52.35 (+0.48), ARNA: 4.55 (+0.01), REGN: 461.39 (+6.35), ABT: 47.15 (+0.15), ENDP: 94.46 (+0.78), AKRX: 52.74 (+1.31), PFE: 35.44 (+0.41), INCY: 93.81 (+1.53), SLXP: 172.96 (+0.15), AMGN: 163.38 (+1.89), MYL: 70.24 (+0.14), LLY: 73.92 (+1.56), BMY: 64.64 (+1.18), GSK: 48.23 (+0.51), ALKS: 63.52 (+0.96), MNKD: 5.25 (unch), OREX: 8.10 (+0.10), NVO: 55.94 (+1.34), ISIS: 65.70 (+1.64), GERN: 4.08 (+0.12), AZN: 69.91 (-0.25), MRK: 57.25 (-0.18), PBYI: 230.48 (+4.03), NVS: 103.58 (+1.01)
UCB's Neupro Positive in Parkinson's Disease Study in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:58PM CST
UCB (UCBJF) announced positive top-line results from two phase III studies on Neupro for early- and advanced-stage Parkinson's disease in Chinese patients.
LCI: 71.15 (+1.92), SCMP: 19.92 (+0.14), BIOD: 1.15 (+0.03)
Week In Review: WuXi NextCode Leads $15 Million Financing In Claritas Genomics
ChinaBio Today - at Seeking Alpha - Sun Feb 08, 3:46AM CST
Deals and Financings WuXi NextCODE Genomics, the newly formed genomic analysis division of China CRO/CMO WuXi PharmaTech (NYSE: WX ), led a $15 million Series B financing in Claritas Genomics (see story ). Claritas is a Boston-based lab that...
MRK: 57.25 (-0.18), WX: 39.12 (-0.49)
UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 6:00PM CST
UCB S.A. (UCBJF) announced that its investigational antiepileptic candidate, brivaracetam, has been accepted for review in the U.S. and the EU.
BCRX: 9.65 (+0.16), AMGN: 163.38 (+1.89), BIOD: 1.15 (+0.03)
Immunomedics Reports Data on Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 3:05PM CST
Immunomedics, Inc., (IMMU) announced data from its lead investigational antibody-drug conjugate (ADC) sacituzumab govitecan from a phase I/II study.
IMMU: 4.14 (+0.07), PFE: 35.44 (+0.41), BIOD: 1.15 (+0.03)
UCB-Neuropore Collaborate for Parkinson's Disease Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 1:10PM CST
UCB S.A. (UCBJF) and Neuropore Therapies Inc. entered into a collaboration agreement for the development and commercialization of Parkinson's disease related therapies.
LCI: 71.15 (+1.92), ENDP: 94.46 (+0.78), BIOD: 1.15 (+0.03)
UCB Initiates Phase III Psoriasis Study on Cimzia with Dermira - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 4:05PM CST
UCB S.A. (UCBJF) and Dermira finished dosing the first set of patients in a phase III development program on Cimzia for moderate-to-severe chronic plaque psoriasis.
SHPG: 248.77 (-5.55), AMGN: 163.38 (+1.89), NVS: 103.58 (+1.01)
Immunomedics: Under-Followed Company With Robust Pipeline And Huge Growth Potential
Bridging the Gap - at Seeking Alpha - Fri Dec 26, 4:17PM CST
IMMU: 4.14 (+0.07)
UCB's Kremers Urban Sale Deal Lapses, Divestiture Plan On - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 2:20PM CST
UCB (UCBJF), Advent International and Avista Capital Partners announced their decision to mutually terminate their deal for the acquisition of UCB's Kremers Urban.
LCI: 71.15 (+1.92), VRX: 207.50 (+1.78), SCMP: 19.92 (+0.14)
UCB Reports Phase III Data on Epilepsy Drug, To File in 2015 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 1:50PM CST
UCB SA (UCBJF) announced positive primary efficacy and safety data from its latest phase III study on its epilepsy candidate, brivaracetam.
LCI: 71.15 (+1.92), VRX: 207.50 (+1.78), SCMP: 19.92 (+0.14)
UCB-Daiichi Sankyo Ink Deal to Sell Vimpat in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 2:20PM CST
UCB SA (UCBJF) and Daiichi Sankyo have signed a deal to jointly commercialize Vimpat for the treatment of epilepsy in Japan.
IPXL: 50.68 (-0.43), VRX: 207.50 (+1.78), SCMP: 19.92 (+0.14)
Immunomedics' Veltuzumab Receives Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 3:20PM CST
Immunomedics' (IMMU) anti-CD20 antibody, veltuzumab, was granted an orphan drug status in the U.S. for the treatment of pemphigus.
BIIB: 425.65 (-0.98), IMMU: 4.14 (+0.07)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 294.79 (+2.52), QLTI: 3.83 (-0.04), VRX: 207.50 (+1.78), AGN: 240.22 (+2.88), SHPG: 248.77 (-5.55), AUXL: 36.47 (-0.06), ABBV: 62.00 (+1.68), SNY: 52.35 (+0.48), ABT: 47.15 (+0.15), ENDP: 94.46 (+0.78), AKRX: 52.74 (+1.31), PFE: 35.44 (+0.41), INCY: 93.81 (+1.53), SLXP: 172.96 (+0.15), MYL: 70.24 (+0.14), AMGN: 163.38 (+1.89), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51), BMY: 64.64 (+1.18), ACHN: 10.36 (+0.14), MRK: 57.25 (-0.18), AZN: 69.91 (-0.25), ICPT: 279.25 (+7.48), TEVA: 66.37 (-0.77), NVS: 103.58 (+1.01)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 294.79 (+2.52), QLTI: 3.83 (-0.04), VRX: 207.50 (+1.78), AGN: 240.22 (+2.88), SHPG: 248.77 (-5.55), AUXL: 36.47 (-0.06), ABBV: 62.00 (+1.68), SNY: 52.35 (+0.48), ABT: 47.15 (+0.15), ENDP: 94.46 (+0.78), AKRX: 52.74 (+1.31), PFE: 35.44 (+0.41), INCY: 93.81 (+1.53), SLXP: 172.96 (+0.15), MYL: 70.24 (+0.14), AMGN: 163.38 (+1.89), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51), BMY: 64.64 (+1.18), ACHN: 10.36 (+0.14), MRK: 57.25 (-0.18), AZN: 69.91 (-0.25), ICPT: 279.25 (+7.48), TEVA: 66.37 (-0.77), NVS: 103.58 (+1.01)
Will Catalyst Pharmaceuticals' (CPRX) Loss Narrow in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:30PM CST
Catalyst Pharmaceuticals Inc, Inc. (CPRX) is expected to report third-quarter 2014 results on Nov 13.
MNK: 129.09 (+1.29), BMRN: 122.20 (+0.12), CPRX: 4.67 (-0.01)
UCB to Sell Generics Business, Focus on Core Segments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:30PM CST
UCB SA (UCBJF) entered into an agreement with Advent International and Avista Capital Partners for the sale of its specialty generics subsidiary for $1.525 billion.
LCI: 71.15 (+1.92), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51), NVS: 103.58 (+1.01)
UCB jettisons U.S. generic business
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:20AM CST
UCB-Amgen Reveals Positive Data on Romosozumab for PMO - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:40PM CDT
UCB SA (UCBJF) and Amgen announced positive results from exploratory analyses of a phase II study on romosozumab in postmenopausal women with low bone mineral density.
GILD: 101.77 (+0.61), AMGN: 163.38 (+1.89), LLY: 73.92 (+1.56)
UCB to Sell Indian Established Brands Portfolio to Dr. Reddy's - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 1:40PM CDT
UCB S.A. (UCBJF) will sell its established brands portfolio in India, to Dr. Reddy's Laboratories Ltd. to focus on core business.
CYTK: 7.26 (+0.19), LCI: 71.15 (+1.92), RDY: 60.41 (+0.22)
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
BIIB: 425.65 (-0.98), ACT: 294.79 (+2.52), VRX: 207.50 (+1.78), PCYC: 258.35 (+0.57), OSIR: 17.56 (+0.84), ACOR: 34.46 (+0.61), HSP: 87.75 (+0.10), AGN: 240.22 (+2.88), MDVN: 132.44 (+0.38), ESRX: 88.85 (+0.38), SHPG: 248.77 (-5.55), ABBV: 62.00 (+1.68), SNY: 52.35 (+0.48), ARNA: 4.55 (+0.01), REGN: 461.39 (+6.35), ABT: 47.15 (+0.15), ENDP: 94.46 (+0.78), AKRX: 52.74 (+1.31), PFE: 35.44 (+0.41), INCY: 93.81 (+1.53), SLXP: 172.96 (+0.15), AMGN: 163.38 (+1.89), MYL: 70.24 (+0.14), LLY: 73.92 (+1.56), BMY: 64.64 (+1.18), GSK: 48.23 (+0.51), ALKS: 63.52 (+0.96), MNKD: 5.25 (unch), OREX: 8.10 (+0.10), NVO: 55.94 (+1.34), ISIS: 65.70 (+1.64), GERN: 4.08 (+0.12), AZN: 69.91 (-0.25), MRK: 57.25 (-0.18), PBYI: 230.48 (+4.03), NVS: 103.58 (+1.01)
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
BIIB: 425.65 (-0.98), ACT: 294.79 (+2.52), VRX: 207.50 (+1.78), PCYC: 258.35 (+0.57), OSIR: 17.56 (+0.84), ACOR: 34.46 (+0.61), HSP: 87.75 (+0.10), AGN: 240.22 (+2.88), MDVN: 132.44 (+0.38), ESRX: 88.85 (+0.38), SHPG: 248.77 (-5.55), ABBV: 62.00 (+1.68), SNY: 52.35 (+0.48), ARNA: 4.55 (+0.01), REGN: 461.39 (+6.35), ABT: 47.15 (+0.15), ENDP: 94.46 (+0.78), AKRX: 52.74 (+1.31), PFE: 35.44 (+0.41), INCY: 93.81 (+1.53), SLXP: 172.96 (+0.15), AMGN: 163.38 (+1.89), MYL: 70.24 (+0.14), LLY: 73.92 (+1.56), BMY: 64.64 (+1.18), GSK: 48.23 (+0.51), ALKS: 63.52 (+0.96), MNKD: 5.25 (unch), OREX: 8.10 (+0.10), NVO: 55.94 (+1.34), ISIS: 65.70 (+1.64), GERN: 4.08 (+0.12), AZN: 69.91 (-0.25), MRK: 57.25 (-0.18), PBYI: 230.48 (+4.03), NVS: 103.58 (+1.01)
UCB's Neupro Positive in Parkinson's Disease Study in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:58PM CST
UCB (UCBJF) announced positive top-line results from two phase III studies on Neupro for early- and advanced-stage Parkinson's disease in Chinese patients.
LCI: 71.15 (+1.92), SCMP: 19.92 (+0.14), BIOD: 1.15 (+0.03)
Week In Review: WuXi NextCode Leads $15 Million Financing In Claritas Genomics
ChinaBio Today - at Seeking Alpha - Sun Feb 08, 3:46AM CST
Deals and Financings WuXi NextCODE Genomics, the newly formed genomic analysis division of China CRO/CMO WuXi PharmaTech (NYSE: WX ), led a $15 million Series B financing in Claritas Genomics (see story ). Claritas is a Boston-based lab that...
MRK: 57.25 (-0.18), WX: 39.12 (-0.49)
UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 6:00PM CST
UCB S.A. (UCBJF) announced that its investigational antiepileptic candidate, brivaracetam, has been accepted for review in the U.S. and the EU.
BCRX: 9.65 (+0.16), AMGN: 163.38 (+1.89), BIOD: 1.15 (+0.03)
Immunomedics Reports Data on Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 3:05PM CST
Immunomedics, Inc., (IMMU) announced data from its lead investigational antibody-drug conjugate (ADC) sacituzumab govitecan from a phase I/II study.
IMMU: 4.14 (+0.07), PFE: 35.44 (+0.41), BIOD: 1.15 (+0.03)
UCB-Neuropore Collaborate for Parkinson's Disease Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 1:10PM CST
UCB S.A. (UCBJF) and Neuropore Therapies Inc. entered into a collaboration agreement for the development and commercialization of Parkinson's disease related therapies.
LCI: 71.15 (+1.92), ENDP: 94.46 (+0.78), BIOD: 1.15 (+0.03)
UCB Initiates Phase III Psoriasis Study on Cimzia with Dermira - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 4:05PM CST
UCB S.A. (UCBJF) and Dermira finished dosing the first set of patients in a phase III development program on Cimzia for moderate-to-severe chronic plaque psoriasis.
SHPG: 248.77 (-5.55), AMGN: 163.38 (+1.89), NVS: 103.58 (+1.01)
Immunomedics: Under-Followed Company With Robust Pipeline And Huge Growth Potential
Bridging the Gap - at Seeking Alpha - Fri Dec 26, 4:17PM CST
IMMU: 4.14 (+0.07)
UCB's Kremers Urban Sale Deal Lapses, Divestiture Plan On - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 2:20PM CST
UCB (UCBJF), Advent International and Avista Capital Partners announced their decision to mutually terminate their deal for the acquisition of UCB's Kremers Urban.
LCI: 71.15 (+1.92), VRX: 207.50 (+1.78), SCMP: 19.92 (+0.14)
UCB Reports Phase III Data on Epilepsy Drug, To File in 2015 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 1:50PM CST
UCB SA (UCBJF) announced positive primary efficacy and safety data from its latest phase III study on its epilepsy candidate, brivaracetam.
LCI: 71.15 (+1.92), VRX: 207.50 (+1.78), SCMP: 19.92 (+0.14)
UCB-Daiichi Sankyo Ink Deal to Sell Vimpat in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 2:20PM CST
UCB SA (UCBJF) and Daiichi Sankyo have signed a deal to jointly commercialize Vimpat for the treatment of epilepsy in Japan.
IPXL: 50.68 (-0.43), VRX: 207.50 (+1.78), SCMP: 19.92 (+0.14)
Immunomedics' Veltuzumab Receives Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 3:20PM CST
Immunomedics' (IMMU) anti-CD20 antibody, veltuzumab, was granted an orphan drug status in the U.S. for the treatment of pemphigus.
BIIB: 425.65 (-0.98), IMMU: 4.14 (+0.07)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 294.79 (+2.52), QLTI: 3.83 (-0.04), VRX: 207.50 (+1.78), AGN: 240.22 (+2.88), SHPG: 248.77 (-5.55), AUXL: 36.47 (-0.06), ABBV: 62.00 (+1.68), SNY: 52.35 (+0.48), ABT: 47.15 (+0.15), ENDP: 94.46 (+0.78), AKRX: 52.74 (+1.31), PFE: 35.44 (+0.41), INCY: 93.81 (+1.53), SLXP: 172.96 (+0.15), MYL: 70.24 (+0.14), AMGN: 163.38 (+1.89), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51), BMY: 64.64 (+1.18), ACHN: 10.36 (+0.14), MRK: 57.25 (-0.18), AZN: 69.91 (-0.25), ICPT: 279.25 (+7.48), TEVA: 66.37 (-0.77), NVS: 103.58 (+1.01)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 294.79 (+2.52), QLTI: 3.83 (-0.04), VRX: 207.50 (+1.78), AGN: 240.22 (+2.88), SHPG: 248.77 (-5.55), AUXL: 36.47 (-0.06), ABBV: 62.00 (+1.68), SNY: 52.35 (+0.48), ABT: 47.15 (+0.15), ENDP: 94.46 (+0.78), AKRX: 52.74 (+1.31), PFE: 35.44 (+0.41), INCY: 93.81 (+1.53), SLXP: 172.96 (+0.15), MYL: 70.24 (+0.14), AMGN: 163.38 (+1.89), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51), BMY: 64.64 (+1.18), ACHN: 10.36 (+0.14), MRK: 57.25 (-0.18), AZN: 69.91 (-0.25), ICPT: 279.25 (+7.48), TEVA: 66.37 (-0.77), NVS: 103.58 (+1.01)
Will Catalyst Pharmaceuticals' (CPRX) Loss Narrow in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:30PM CST
Catalyst Pharmaceuticals Inc, Inc. (CPRX) is expected to report third-quarter 2014 results on Nov 13.
MNK: 129.09 (+1.29), BMRN: 122.20 (+0.12), CPRX: 4.67 (-0.01)
UCB to Sell Generics Business, Focus on Core Segments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:30PM CST
UCB SA (UCBJF) entered into an agreement with Advent International and Avista Capital Partners for the sale of its specialty generics subsidiary for $1.525 billion.
LCI: 71.15 (+1.92), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51), NVS: 103.58 (+1.01)
UCB jettisons U.S. generic business
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:20AM CST
UCB-Amgen Reveals Positive Data on Romosozumab for PMO - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:40PM CDT
UCB SA (UCBJF) and Amgen announced positive results from exploratory analyses of a phase II study on romosozumab in postmenopausal women with low bone mineral density.
GILD: 101.77 (+0.61), AMGN: 163.38 (+1.89), LLY: 73.92 (+1.56)
